Eli Lilly and Co

UCI MIND mourns the loss of founder Dr. Carl Cotman, who established the UCI Alzheimer’s Disease Research Center and recruited prominent researchers. His legacy includes the Southern California Alzheimer’s Disease Research Conference and the UCI ADRC brain bank. UCI MIND plans to honor Cotman through awards and donations. The article also highlights recent collaborations, service awards, and initiatives like the Beall Scholar Program aimed at inspiring young minds in dementia research.

Biopharma updates: deals, partnerships, grants, preclinical data, and other news involving Alkem, Astellas, Bio-Thera, Boehringer, Ciconia, Circle Pharma, Eli Lilly, Gedeon Richter, Gemma, Insitro, Johnson & Johnson, Nona, Overt Bio, Qinotto, Sonnet, Sumitomo, Takeda, Xortx.

The Outsourcing Facilities Association (OFA) sued the FDA for removing tirzepatide from the federal drug shortage list without proper notice. Tirzepatide, a diabetes drug by Eli Lilly, also benefits patients with sleep apnea and heart failure. The FDA's action prevents OFA-represented facilities from producing compounded versions, impacting patient care and facility investments.

Goodwin's Life Sciences team advises insitro on three strategic agreements with Eli Lilly to advance metabolic disease treatments, leveraging insitro's AI/ML-based platform and Lilly's drug delivery expertise.

Pharmaceutical companies are racing to develop obesity drugs more potent than Novo Nordisk's Wegovy and Eli Lilly's Zepbound. Key trials in the next six months will reveal contenders like Lilly's Zepbound, Novo's dual-acting cagrisema, Amgen's maritide, and Roche's GLP-1 pill CT-996. Additionally, efforts to preserve muscle mass and explore new drug targets like CB1 inhibition are underway.

Eli Lilly appoints its first chief AI officer.

Eli Lilly appoints Thomas Fuchs as its first chief AI officer. Telehealth companies face frustration with DEA as pandemic flexibilities near expiration. Particle Health and Epic Systems dispute data sharing practices. FDA's Tala Fakhouri discusses AI's role in clinical trials, emphasizing data access challenges. Multiple health tech companies announce significant fundraises and deals.

The global High Potency APIs (HPAPIs) market is projected to reach $46.9 Billion by 2030, driven by the expansion of oncology, hormonal, and endocrine therapies. Key factors include the rise in cancer diagnoses, targeted therapies, advancements in drug delivery, and the expansion of CMOs specializing in HPAPI production.

Antag Therapeutics' AT-7687, a GIPR antagonist, receives FDA IND acceptance for phase 1 trial in healthy lean and obese individuals, exploring combination with semaglutide. Founded in 2017, Antag aims to treat obesity and cardiometabolic diseases, leveraging research by co-founder Prof. Jens Juul Holst.